Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ASH 2014 | Phase III study shows carfilzomib is an effective addition to standard myeloma therapy

Andrew Stewart • 5 Dec 2013
ASH 2014
Multiple Myeloma Carfilzomib Dexamethasone Lenalidomide

At a press conference during the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Keith Stewart (Mayo Clinic, Scottsdale, AZ) discusses the randomised, open-label, multicentre phase III ASPIRE study. The results of this study suggest carfilzomib combined with standard multiple myeloma therapy (combination of lenalidomide and dexamethasone) improves treatment responses in patients with relapsed or treatment-resistant multiple myeloma.

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals